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Drugs: Systematic Search for Clinical Practice Guidelines
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Abstract: Gastrointestinal (GI) bleeding is a frequently encountered
and very serious problem in emergency room patients who are currently
being treated with anticoagulant or antiplatelet medications. There is,
however, a lack of clinical practice guidelines about how to respond to
these situations. The goal of this study was to find published articles that
contain specific information about how to safely adjust anticoagulant
and antiplatelet therapy when GI bleeding occurs.
The investigators initiated a global search on the PubMed and
Google websites for published information about GI bleeding in
the presence of anticoagulant or antiplatelet therapy. After eliminating
duplicate entries, the medical articles that remained were screened
to narrow the sets of articles to those that met specific criteria. Articles
that most closely matched study criteria were analyzed in detail
and compared to determine how many actual guidelines exist and
are useful.
We could provide only minimal information about appropriate
therapeutic strategies because no articles provided sufficient specific
advice about how to respond to situations involving acute GI bleeding
and concurrent use of anticoagulant or antiplatelet drugs. Only 4 articles
provided enough detail to be of any use in an emergency situation.
Clinical practice guidelines and also clinical trials for GI hemor-
rhaging should be expanded to state in which situations the use of
anticoagulant or antiplatelet drugs should be suspended and the medi-
cations should later be resumed, and they should state the level of risk
for any particular action.
(Medicine 94(1):e377)
Abbreviations: ASA = acetylsalicylic acid, COX-2 = cyclo-
oxygenase-2, GI = gastrointestinal, NSAID = nonsteroidal anti-
inflammatory drug, PPI = proton-pump inhibitor, SSRI = selective
serotonin reuptake inhibitor.
INTRODUCTION
G astrointestinal (GI) bleeding is frequently encountered inemergency room patients who are currently being treated
with anticoagulant or antiplatelet medications for an underlying
medical condition. It is a serious problem, especially in the
elderly and/or multimorbid patients, and it presents the emer-
gency room physician with a dilemma. On the one hand, any
anticoagulant and antiplatelet treatment should be discontinued
to help stopping the acute bleeding. On the other hand, dis-
continuing this type of therapy can significantly increase the
risk for cardiovascular or cerebrovascular complications
because of the underlying disease.
The number of patients who are being prescribed antic-
oagulant or antiplatelet therapy to either treat or prevent car-
diovascular and cerebrovascular diseases is increasing.1–4 The
downside of these therapies, however, is that they increase the
risk for life-threatening bleeding, most of which occur as GI or
intracerebral bleeding.5 The relative risk for upper GI bleeding,
in particular, increases up to 10% in patients being treated with
these therapies, and the annual risk for upper GI bleeding
occurring in such patients is 1.5% to 4.5%.6–8 This compli-
cation puts affected patients into an acutely life-threatening
situation because the mortality from GI bleeding ranges from
1% to 13%.9–11
Given how often this life-threatening situation is encoun-
tered in emergency rooms, there is a surprising lack of data with
respect to the problem. We found only 2 controlled studies that
have investigated whether or when the use of anticoagulant or
antiplatelet medications should be resumed after GI bleeding
has ceased.12,13 Results of the 2 studies do not provide a
consistent guideline with respect to adjusting medications.
The timeframe for resuming therapy was anywhere between
20 and 90 days after GI bleeding had stopped.12,13 Results of
one of the studies indicated that permanently stopping antic-
oagulant therapy in patients being treated with warfarin greatly
increases the risk for thromboembolic events and even
death.12,13
The goal of this study was to find published information
that provided specific advice about how to safely adjust antic-
oagulant and antiplatelet therapy when GI bleeding occurs.
METHODS
Because there were no clinical practice guidelines cur-
rently available to emergency room physicians, our team was
looking for relatively recent articles that might provide, if not
explicit guidelines, at least some kind of advice that addressed
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how to best respond to a situation of GI bleeding in patients
taking anticoagulant or antiplatelet drugs. No ethical approval
was necessary to conduct the study because no patient data were
collected or analyzed.
Overview of Study Design
The study consisted of a series of searches in the medical
literature on 2 Internet websites using the terms ‘‘gastrointes-
tinal hemorrhage,’’ ‘‘cardiovascular diseases,’’ ‘‘guideline,’’
‘‘platelet aggregation inhibitors,’’ and ‘‘anticoagulants’’ as
single terms or as PubMed MeSH terms to provide a list of
titles for articles that might contain the type of clinical practice
information we were seeking. The search included articles
published through March 2013. The list of articles retrieved
in the searches was then screened to narrow the set of entries to
those that met 2 sets of criteria and eliminate entries that did not
satisfy the goal of the study.
The first set of criteria was designed to ensure a focus on
practical guidelines rather than general research in the areas of
GI bleeding or cardiovascular therapies, that the entries com-
prised a relatively homogeneous study population in terms of
genetic and lifestyle characteristics to which any guidelines
might apply, the entries represented the results of relatively
recent research, and consistency with respect to the terminology
used in the articles. The second set of criteria was designed to
narrow the set of eligible entries to ones that mentioned some
guidelines, advice, suggestions, or otherwise relevant infor-
mation about clinical practices.
A third stage of review eliminated articles that did not
contain specific recommendations with respect to how to adjust
therapeutic regimens for GI bleeding and concurrent cardio-
vascular conditions. After a set of articles had been identified
that most closely matched all criteria, the relevant information
in each article was analyzed in detail and compared with that in
other articles to determine howmany actual guidelines exist and
are useful. At least 2 members of the investigating team
reviewed each entry at all stages of the selection process.
Data Sources and Searches
The initial Internet searches were on the PubMed website,
first using the term ‘‘Gastrointestinal hemorrhage,’’ followed by
an advanced search with the terms ‘‘Cardiovascular diseases
AND Gastrointestinal hemorrhage,’’ ‘‘Cardiovascular diseases
AND Gastrointestinal hemorrhage AND guideline,’’ and ‘‘Car-
diovascular diseases AND platelet aggregation inhibitors OR
anticoagulants AND guideline.’’ The second set of searches was
on the Google website using the same search terms in the same
order. The articles gleaned from all of these searches were
collated and the duplicate entries deleted.
Study Selection
1 To test the initial set of criteria that would be used to
screen articles at this stage, a pilot set of 100 titles and
their associated abstracts were reviewed by I.K.G. and one
of the coauthors. If necessary, the criteria were modified. If
no abstract was available for an article but the title appeared
to be relevant, we obtained the full text of the article
for review.
2 All remaining titles and their associated abstracts were then
screened by I.K.G. and one of the coauthors using the initial
set of selection criteria in a predetermined sequence. First,
articles that were clearly not guideline articles were
eliminated. Second, all articles that were not written
in English were eliminated. Third, all articles published
>5 years prior to March 2013 were eliminated. Fourth,
all articles that did not originate in Europe, the United
States, or Canada were eliminated. Again, if no abstract
was available for an article, but the title appeared to
be relevant, we obtained the full text of the article for
review.
3 To test the criteria that would be used for screening the
smaller and more focused group of articles in the next stages
of the study, the full texts of a pilot set of 10 papers from this
group were read and discussed by I.K.G. and one of the
coauthors of this study.
4 The full texts of all remaining articles were then screened by
I.K.G. and one of the coauthors of this study. Upon initial
reading of the texts, any articles found to not meet the initial
selection criteria were eliminated. Then articles that did not
mention any information about patient care or whose focus
was obviously non-GI-related hemorrhaging were elimi-
nated.
Data Extraction and Quality Assessment
In their evaluations of the full texts of the articles, the
reviewers noted whether an article contained information about
how to proceed with respect to stopping, continuing, or adjust-
ing dosages of specific anticoagulant or antiplatelet drugs in use
at the time of GI bleeding, with respect to the use of other types
of interventions for GI bleeding, and with respect to whether to
resume specific anticoagulant or antiplatelet drugs after GI
bleeding had stopped, and if so, when and at what dosages.
The results of the 2 investigators were compared. Any differ-
ences that could not be resolved were referred to EB, MS, or the
primary author of this study.
Data Synthesis and Analysis
The clinical practice advice in the remaining articles was
evaluated again in detail and compared by 2 of the coauthors and
the findings summarized. The 4 finally relevant articles were
identified by both searches, PubMed and Google.
RESULTS
The combined results for searches of the PubMed and
Google sites were 81 320 articles after eliminating duplicate
entries. However, despite the large number of articles initially
identified on those sites, almost no articles contained opera-
tionally useful recommendations with respect to strategies for
reducing or eliminating the use of anticoagulant and antiplatelet
drugs when GI bleeding is present in patients. Of the initial
49 020 articles originally extracted from PubMed, only 56
articles remained eligible for further assessment; of the
32 300 articles originally extracted from the Google site, only
20 articles remained eligible for further assessment.
After reading the full text of all eligible articles, 59 were
excluded because they were found to not meet the initial
selection criteria, did not mention information about patient
care, or discussed situations of non-GI-related hemorrhaging.
Among the 17 remaining articles that provided some type of
information about patient care in a case of GI hemorrhaging,
gastroenterology guidelines tended to primarily focus on the
bleeding-associated risk for patient, and cardiovascular guide-
lines tended to focus on the risk that is associated with
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discontinuing anticoagulant or antiplatelet therapy. After eval-
uating the specific guidelines or suggestions, 8 articles were
eliminated because they contained very general information that
was not considered useful from a clinical practice standpoint.
Only 4 of the 9 remaining articles were found to contain useful
advice for an emergency room setting, only 1 of which focused
on the interaction between cardiovascular medications and GI
hemorrhaging. The specific recommendations of these 4 articles
are summarized in Table 1. One of those articles featured a
combined cardiovascular and GI focus,14 and 3 of them clearly
revealed a GI focus.15–17
Guidelines With a Combined Cardiovascular and
GI Focus
Our search identified 1 article published by the British
Society of Gastroenterology that addressed both cardiovascular
and GI aspects of managing anticoagulant and antiplatelet
therapy in patients undergoing endoscopic procedures.14 In this
article, some concrete advice is provided about how to proceed
in an actual emergency situation. It is clearly stated that an acute
GI hemorrhage in patients on anticoagulant or antiplatelet
medications is a high-risk situation and that the immediate risk
to the patient from a hemorrhage may outweigh the risk of
thrombosis that might occur if anticoagulant or antiplatelet
therapy is stopped. It should be noted that patients need to
be assessed on an individual basis because it is not possible to
provide unequivocal guidance to cover all of the possible
situations that might be encountered in patients. It should also
be noted that endoscopy should be attempted as soon as safely
possible after immediate consultation between the patient’s
cardiologist and the specialist doing the endoscopy.
Early therapeutic endoscopic intervention may achieve
hemostasis with minimal or no cessation of anticoagulant or
antiplatelet therapy and should be the first goal if possible. This
recommendation is stated as an evidence grade IV, recommen-
dation grade C. For patients with high-risk conditions who are
being treated with warfarin, the article states that warfarin can
be discontinued either with or without the substitution of
heparin, depending on the severity of the hemorrhaging and
the risk of discontinuing anticoagulant therapy. For the patient
being treated with clopidogrel, the recommendation is not to
discontinue the medication without discussing the action with a
cardiologist beforehand. There is a high risk of acute myo-
cardial infarction or death in patients with coronary stents if
clopidogrel is discontinued, particularly if it is discontinued
soon after the stent has been implanted and for up to 1 year after
implantation. If clopidogrel therapy must be discontinued, the
action should be limited to a maximum of 5 days because the
risk of stent thrombosis increases after this interval. The latter
recommendation is stated as an evidence grade III, recommen-
dation grade B.
Guidelines With a GI Focus
Eight of the 17 articles were associated with a gastroenter-
ology society or association or provided international consensus
information about a specific GI situation, but most of them
provided little operational advice with respect to concurrent
cardiovascular conditions.15–22 Only 3 of the articles provided
some concrete guidance with respect to adjusting anticoagulant
and antiplatelet therapies in situations of GI bleeding,15–17 and
their results are summarized in Table 1.
American College of Gastroenterology guidelines for
managing patients with a bleeding ulcer15 also provide advice
about how to handle anticoagulant or antiplatelet therapies,
specifically with respect to therapy management, when to
resume therapy that has been suspended, and the need to
differentiate between primary and secondary prevention when
prescribing low-dose aspirin therapy. When bleeding occurs,
the guidelines recommend that acetylsalicylic acid (ASA) or
any nonsteroidal anti-inflammatory drug (NSAID) should be
stopped. For long-term prevention of recurring bleeding ulcers,
the recommendation is that in patients with NSAID-associated
bleeding ulcers, the need for NSAIDs should be carefully
assessed and, if possible, NSAIDs should not be resumed. In
patients who must resume NSAIDs, a cyclooxygenase-2 (COX-
2)-selective NSAID at the lowest effective dose along with a
daily proton-pump inhibitor (PPI) is recommended. This is
stated as a strong recommendation. In patients with low-dose
TABLE 1. Recommendations Available According to the Results of a Review of >81000 Articles Culled From the Published
Literature in 2013 on Topics Related to GI Bleeding in Patients Taking Anticoagulant and Antiplatelet Drugs
Guideline
Source
Is Long-Term
Use of ASA/NSAID
Permissible?
Is ASA and
PPI Preferred
to
Clopidogrel?
Stop Anticoagulant
and Antiplatelet
Medications During
Acute Bleeding?
Is the Use of ASA
Permissible Again
After Bleeding
Stops?

Is the Use of Clopidogrel
Permissible Again After
Bleeding Stops?
DSGHy Yes, but add a PPI Yes Yes Yes, 24 h after bleeding stops,
but add a high-dose PPI
Yes, 3 d after bleeding
stops
ACGz Yes, but add a PPI Not discussed Yes Yes, 1–7 d after bleeding stops Not discussed
ICG§ Yes, but add a PPI Yes Yes Yes, as soon as possible
after bleeding stops
Not discussed
BSGjj Not discussed Not discussed Yes Not discussed Yes, 5 d after bleeding stops
ACG¼American College of Gastroenterology, ASA¼ acetylsalicylic acid, BSG¼British Society of Gastroenterology, DSGH¼Danish Society
for Gastroenterology and Hepatology, GI¼ gastrointestinal, ICG¼ international consensus guidelines, NSAID¼ nonsteroidal anti-inflammatory
drug, PPI¼ proton-pump inhibitor.
When cardiovascular risk outweighs gastrointestinal bleeding risk.
yLaursen et al.16
zLaine and Jensen.15
§ Barkun et al.17
jjVeitch et al.14
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ASA-associated bleeding ulcers, it is suggested that the need for
ASA should be assessed. If ASA had been prescribed for
secondary prevention (ie, in the case of established cardiovas-
cular disease), the ASA should be resumed in most patients as
soon as possible after bleeding ceases (ideally within 1–3 days,
and certainly within 7 days). Long-term daily PPI therapy
should also be provided in this situation. If ASA had been
prescribed for primary prevention (ie, no established cardio-
vascular disease), antiplatelet therapy should probably not be
resumed in most patients. This recommendation is, however,
conditional, depending on the actual circumstances for each
patient (Table 1).
The Danish Society for Gastroenterology and Hepatology
guidelines for managing bleeding gastroduodenal ulcers16
recommend suspending treatment with ASA, clopidogrel,
NSAIDs, and selective serotonin reuptake inhibitors (SSRIs)
in the presence of a bleeding ulcer. They note that platelet
function in normal subjects is inhibited for up to 5 days after the
withdrawal of clopidogrel or aspirin, but presumably for a
shorter time in bleeding patients. Consequently, treatment with
both drugs can be suspended for up to 24 hours until the
bleeding has stopped and the situation has stabilized. In the
case of patients with bleeding peptic ulcers who require sec-
ondary cardiovascular prophylaxis, the recommendation is to
resume ASA again as soon as the cardiovascular risk outweighs
the GI risk. Low-dose ASA can be resumed after 24 hours if
there is no longer any sign of bleeding and a high-dose
intravenous PPI is given along with it. They recommend
unnecessary NSAID intake be discontinued. They note that
treatment with clopidogrel or other thienopyridines in patients
with coronary stents can be resumed after 3 days, but if there is
any doubt whether this is the appropriate approach, a cardiol-
ogist should be consulted. They also note that treatment with an
SSRI can be resumed after 5 days. For patients in need of long-
term treatment with ASA or a NSAID, the recommendation is to
prescribe prophylactic treatment with a PPI at standard dosage.
In patients who need antiplatelet therapy for conditions other
than coronary stents, the recommendation is a PPI in combi-
nation with 75 mg ASA as the preferred therapeutic choice
rather than monotherapy with clopidogrel (Table 1).
Biondi-Zoccai et al23 mention that prematurely stopping
antiplatelet therapy is the most significant risk factor for stent
thrombosis among patients with coronary stents. Therefore,
continuing with ASA treatment is important because the risk
of developing arterial thrombosis almost doubles when ASA
treatment is stopped in patients for whom this type of treatment
is the most appropriate choice. Sung et al24 mention that the
mortality rate is lower in patients who are on a low-dose ASA
regimen combined with a high-dose intravenous PPI after an
endoscopic procedure for a bleeding ulcer; there is no statisti-
cally significant increase in the rebleeding rate. A set of
international consensus guidelines for managing patients with
nonvariceal upper GI bleeding17 states that in patients who are
receiving anticoagulants, the recommendation is to correct the
coagulopathy but not to delay endoscopy. In patients who are
being treated with low-dose ASA, the ASA therapy should be
resumed as soon as the risk for cardiovascular complication is
thought to outweigh the risk for a hemorrhage. In patients who
need antiplatelet therapy for conditions other than coronary
stents, a PPI in combination with 75 mg ASA should be the
preferred therapeutic choice rather than monotherapy with
clopidogrel. These guidelines note that clopidogrel alone has
a higher risk for a recurrence of bleeding than does ASA
combined with a PPI in patients who require cardiovascular
prophylaxis and who also previously had a bleeding ulcer. For
patients who have either current upper GI bleeding or a history
of bleeding ulcers and who require a NSAID, the recommen-
dation is to use a PPI together with a COX-2 inhibitor rather
than to use COX-2 inhibitors alone to reduce the risk of
recurring bleeding. They, however, note that even treatment
with a traditional NSAID and a PPI is still associated with a
clinically significant risk of a recurring bleeding ulcer.
All 8 articles suggested temporarily suspending anticoa-
gulant and antiplatelet therapy in a situation that involved acute
bleeding and, in the case of high-risk patients (eg, patients with
critical coronary artery disease and coronary stents), suggested
that the treatment plan should be discussed between specialists
in the 2 medical disciplines.15–22
Guidelines With a Cardiovascular Focus
In the 8 of the 17 articles identified as containing relevant
cardiovascular guidelines, only minimal information is pro-
vided about how to proceed with anticoagulant or antiplatelet
therapy in a situation of acute GI bleeding.25–32 In fact, none of
them explicitly mention directions for addressing situations
involving GI bleeding. The article that provides the most
information about handling an acute bleeding situation is the
European Society of Cardiology guideline for the management
of acute coronary syndromes in patients presenting without
persistent ST-segment elevation.26 Here it is stated that major
bleeding events such as GI, retroperitoneal, intracranial, or
other severe blood loss requires the interruption and neutraliz-
ation of both anticoagulant and antiplatelet treatment if bleeding
cannot be controlled by other appropriate interventions. In this
situation, neither anticoagulant nor antiplatelet agents should be
reintroduced until strict control of the hemorrhage has been
achieved for at least 24 hours. The guideline, however, also
mentions that it may not be necessary to interrupt treatment with
antithrombotic agents if complete control of the hemorrhage can
be achieved with local measures. It is further suggested that in
clinical practice, the risk of discontinuing antithrombotic medi-
cations must be weighed against the risk of a thrombotic event,
particularly if the patient has a stent implant. The opinion at this
time is that discontinuing antiplatelet and antithrombotic drugs
leads to an increased risk of ischemic events, particularly stent
thrombosis after percutaneous coronary intervention.
DISCUSSION
What we find in this study is that, with one exception,
neither current gastroenterology nor cardiology guidelines
focus on the interaction between the therapies being prescribed
for GI bleeding and cardiovascular conditions. So, in an emer-
gency situation, there are only a few operationally useful
recommendations in the published literature with respect to
strategies for modifying prescribed therapeutic regimens to
address the risks related to both the hemorrhage and the
underlying disease. This creates the very real possibility of
an adverse outcome that could have been prevented if there had
been adequate and clearly presented information available
about how to adjust anticoagulant and antiplatelet therapies
in these situations.
Even in the 17 articles that we found to offer some type of
guideline, only minimal information and advice is provided.
Although it is generally recommended that anticoagulant and
antiplatelet therapies be discontinued in the case of acute, life-
threatening GI bleeding, particularly for patients with an under-
lying complex cardiovascular disease, and that the clinicians in
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the respective medical specialties should discuss the patient’s
situation immediately, there is no clear advice about how to
proceed after the episode of acute bleeding. The lack of clear
clinical practice guidelines further complicates patient care in
an emergency room setting because the extra time needed for
clinicians in the respective medical specialties to discuss each
individual patient’s situation can delay critically needed emer-
gency care and therefore be detrimental to patient outcome. It is
obvious that clinical practice guidelines play a crucial role in
patient management. Therefore, we recommend that current
clinical practice guidelines be expanded to include specific
advice about how to adjust therapeutic regimens in patients
with GI bleeding. The guidelines should clearly state in what
situations the use of a specific anticoagulant or antiplatelet drug
should be suspended, in which situations specific medications
should be resumed after the GI hemorrhage has stopped (pre-
ferably providing precise timeframes and dosages for resuming
the drugs), and the level of risk for any particular action.
Nevertheless, it must be mentioned that patients often
exhibit a poor adherence to gastroprotective agents when using
NSAIDs or low-dose ASA. This fact also seems to critically
contribute to the incidence of GI bleeding, since a significant
proportion of patients using NSAID and ASA with a high risk
for GI bleeding had not received prophylaxis with gastropro-
tective agents before ulcer bleeding. These bleeding episodes
might be preventable with better adherence to gastroprotective
agent use.33 Only about 24% of elderly and often multimorbid
patients taking NSAIDs also receive also a coprescription for
gastroprotective agents.34
Current guidelines recommend testing for Helicobacter
pylori infection among users of low-dose ASA who are at high
risk for developing ulcers. A recent study demonstrated that the
long-term incidence of recurrent ulcer bleeding with ASA use is
low afterH pylori infection is eradicated. This demonstrates that
the eradication of H pylori might be an important factor in the
prevention of GI bleeding, in particular, in high-risk patients.35
A completely new player affecting the risk for GI bleeding
are the new-generation oral anticoagulants, which include
thrombin and factor Xa inhibitors. These drugs are more and
more frequently used, especially in older and multimorbid
patients. Although little is known about whether these drugs
increase patients’ risk for GI bleeding, it seems these new-
generation oral anticoagulants cause an increased risk of GI
bleeding compared with standard care.36
As limitations of the study must be recognized that we
were able to provide only minimal information about appro-
priate therapeutic strategies. Relevant information might be
missing because the study did not include articles that were
written in languages other than English or that originated from a
geographic area outside Europe, Canada, and the United States.
The strength of the study, however, is that this study is the only
known global search for relevant articles in the published
literature. The pool of eligible articles was restricted so that
it encompassed a fairly homogeneous study population geneti-
cally and culturally, which enabled a comparison of the recom-
mendations that we did find. Limiting the articles to ones
written in English reduced the risk of errors in translation
and ensured a consistent use of terminology across the articles.
We realize that providing precise advice about how to
proceed both at the time of the emergency and in the days
following cessation of GI bleeding might be difficult. There-
fore, there should be a discussion and ultimately a consensus
among gastroenterologists and cardiologists with respect to the
benefit-risk ratios for specific types of emergency situations.
For example, it is necessary to answer questions such as the
following: ‘‘What are the risks (stated as percentages) for a
patient with upper GI bleeding who is being treated with
clopidogrel, and after how many days should clopidogrel be
resumed?’’ Ultimately, it might be necessary to conduct clinical
trials to further define and answer these types of questions.
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